BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 27634140)

  • 1. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
    Wilke M
    Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
    Glöckner A
    Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
    Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial.
    Timsit JF; Azoulay E; Schwebel C; Charles PE; Cornet M; Souweine B; Klouche K; Jaber S; Trouillet JL; Bruneel F; Argaud L; Cousson J; Meziani F; Gruson D; Paris A; Darmon M; Garrouste-Orgeas M; Navellou JC; Foucrier A; Allaouchiche B; Das V; Gangneux JP; Ruckly S; Maubon D; Jullien V; Wolff M;
    JAMA; 2016 Oct; 316(15):1555-1564. PubMed ID: 27706483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.
    Vekeman F; Weiss L; Aram J; Ionescu-Ittu R; Moosavi S; Xiao Y; Cheng WY; Bhak RH; Tawadrous M; Capparella MR; Montravers P; Duh MS
    BMC Infect Dis; 2018 Aug; 18(1):438. PubMed ID: 30157797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
    Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
    Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.
    Boonstra JM; van der Elst KC; Veringa A; Jongedijk EM; Brüggemann RJ; Koster RA; Kampinga GA; Kosterink JG; van der Werf TS; Zijlstra JG; Touw DJ; Alffenaar JWC
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
    Kofla G; Ruhnke M
    Eur J Med Res; 2011 Apr; 16(4):159-66. PubMed ID: 21486730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida Surveillance in Surgical Intensive Care Unit (SICU) in a Tertiary Institution.
    Liew YX; Teo J; Too IA; Ngan CC; Tan AL; Chlebicki MP; Kwa AL; Lee W
    BMC Infect Dis; 2015 Jul; 15():256. PubMed ID: 26137997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
    Farmakiotis D; Tarrand JJ; Kontoyiannis DP
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
    Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
    Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of echinocandin regimens by pharmacokinetic/pharmacodynamic analysis against Candida spp. in paediatric patients.
    Xu G; Zhu L; Liao S; Ge T; Yang J
    Int J Antimicrob Agents; 2015 Dec; 46(6):631-41. PubMed ID: 26602452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.
    Sidhu MK; van Engen AK; Kleintjens J; Schoeman O; Palazzo M
    Curr Med Res Opin; 2009 Aug; 25(8):2049-59. PubMed ID: 19575628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Echinocandin to fluconazole step-down therapy in critically ill patients with invasive, susceptible Candida albicans infections.
    van der Geest PJ; Rijnders BJ; Vonk AG; Groeneveld AB
    Mycoses; 2016 Mar; 59(3):179-85. PubMed ID: 26707572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.